Liver is a vital organ and is routinely exposed to toxins. Carbon tetrachloride is one such noxious agent which cause toxicity in liver when CYP450 enzyme bio-activates it. Many hepatoprotective agents are available in market with severe side effects. Appropriate agent is required to combat such liver problems. Azole compounds have much therapeutic values in many diseases. Based upon this fact, present study is aimed to evaluate the repurposing of Itraconazole in the prevention of hepatic fibrosis via inhibition of cytochrome P450 pathway. For in-vitro evaluation of cyto-protective effects in HepG2 cells (untreated and treated groups), cell viability assays, antioxidant evaluation, enzyme linked immunosorbent assay (ELISA) and immunocytochemistry was used. For in-vivo evaluation, CCl4 induced liver fibrotic rat model was used and post treated evaluation was done by blood biochemistry, hematoxylin and eosin (H&E) staining and gene expression profiling. Results of the current study indicated hepatoprotective role of itraconazole via inhibition of CYP450 pathway inhibition. Therefore, Itraconazole use could be a potential therapeutic approach to prevent liver fibrosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p-STAT3 Axis.
Adv Sci (Weinh)
December 2024
Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
There is an urgent necessity to devise efficient tactics to tackle the inevitable development of resistance to osimertinib, which is a third-generation epidermal growth factor receptor (EGFR) inhibitor used in treating EGFR-mutant nonsmall cell lung cancer (NSCLC). This study demonstrates that combining itraconazole with osimertinib synergistically reduces the proliferation and migration, enhances the apoptosis of osimertinib-resistant cells, and effectively inhibits the growth of osimertinib-resistant tumors. Mechanistically, itraconazole combined with osimertinib promotes the proteasomal degradation of sonic hedgehog (SHH), resulting in inactivation of the SHH/Dual-specificity phosphatase 13B (DUSP13B)/p-STAT3 and Hedgehog pathways, suppressing Myc proto-oncogene protein (c-Myc).
View Article and Find Full Text PDFDematiaceous Molds.
Infect Dis Clin North Am
December 2024
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Belfer 610, Bronx, NY 10461, USA. Electronic address:
Article Synopsis
- Dematiaceous molds are dark environmental molds found worldwide, particularly in tropical and subtropical areas, with common types including Bipolaris, Cladophialophora, Exophiala, and Alternaria.
- These molds can cause a variety of diseases in both healthy and immunocompromised individuals, leading to issues like skin infections, allergic reactions, pneumonia, and sometimes serious systemic infections.
- Treatment generally involves antifungal medications such as itraconazole, voriconazole, or posaconazole, combined with measures to address the source of infection and reduce immune suppression, while efforts are underway to enhance diagnostic methods and treatment options due to high mortality rates associated with severe cases.
Epidemiology and Antifungal Susceptibilities of Clinically Isolated Species in Tertiary Hospital of Southeast China.
Infect Drug Resist
December 2024
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Article Synopsis
- This study investigates the rise of fungal infections in Southeast China, focusing on the prevalence and antifungal resistance of specific species at a Shanghai hospital over four years (2018-2022).
- A total of 253 isolates were identified, with certain species being more prevalent, particularly from the Department of Infectious Disease and primarily isolated from sputum samples.
- Results indicated that non-wild-type isolates showed significant resistance to amphotericin B, while most were susceptible to triazoles, particularly posaconazole, highlighting the need for better management of fungal infections in the region.
Prevalence, virulence factors and antifungal susceptibility of oral isolates of Candida albicans from patients with cystic fibrosis in Mexico.
Rev Iberoam Micol
December 2024
Universidad Autónoma de Nuevo León, Departamento de Microbiología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico. Electronic address:
Background: Candida species are frequently isolated from the oral cavity of patients with cystic fibrosis. However, the information on the role of Candida in cystic fibrosis is scarce.
Aims: This study aimed to evaluate the prevalence, virulence profile and antifungal susceptibility of oral isolates of Candida albicans recovered from patients with cystic fibrosis.
Deconvoluting zavegepant drug-drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics.
Clin Transl Sci
December 2024
Pfizer Inc., Groton, Connecticut, USA.
Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and P-glycoprotein [P-gp] inhibitor) on the pharmacokinetics of intranasal/oral zavegepant and the effects of rifampin (a strong inducer of CYP3A4 and P-gp; and an inhibitor of organic anion transporting polypeptide 1B3 [OATP1B3]) on oral zavegepant in healthy participants. In the intranasal/oral zavegepant-itraconazole cohort, participants received a single 10-mg dose of zavegepant nasal spray on Day 1, followed by oral zavegepant (50 mg) on Day 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!